This suggests that although hypercholesterolemia increases the risk of cardiovascular and metabolic disorders, the reduction of this risk is associated with the improvement in both plasma lipids and with the independent inhibitory action of atorvastatin on the post-translational prenylation of small guanosine-5’-triphosphate-binding proteins, leukocyte function-associated antigen-1 intercellular adhesion molecule-1 interaction or nuclear factor-κB pathway [19,20]. The gene discussed is ICAM1; the disease is metabolic disease.